-
Study aim
-
Assessment of response to treatment in anemia (iron deficiency) after CABG in Adults
-
Design
-
This study is a before and after, non-Randomized, single blind clinical trial. After obtaining patient consent and the approval of the ethics committee and the selection based on the inclusion and exclusion criteria, patients enter the study.Each patient in this study is also in the control and intervention group. The number of study samples is 142 patients and the sample size is collected using available samples.
-
Settings and conduct
-
In this study, patients are first tested for ferritin, TIBC and reticulocytes. Oral therapy (ferrous sulfate) is started based on the results of experiments to treat iron deficiency anemia. The above tests are repeated one week later to evaluate the treatment. If the response to treatment is appropriate, the patient will be monitored once and up to three times a month for CBC, TIBC, ferritin, and reticulocytes. Injectable iron is used if the tests are not appropriate one week after the start of oral iron, and the same follow-up is performed quarterly.This study is being performed at Shahid Rajaei Hospital in Tehran.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria:Patients are candidates for CABG for the first time
Age between 18 until 72 years Exclusion criteria:Kidney disorders, Autoimmune diseases
-
Intervention groups
-
In this study, adult patients who have low hemoglobin after an CABG on the last day of their stay at the ICU are included in the study. First, the desired tests are taken from the patients and the patients enter the before phase of the intervention, and in the next step, after giving the pill or ferrosulfate ampoule according to the specified protocol, the next tests are taken and the patients enter the after phase of the intervention and the result is recorded.
-
Main outcome variables
-
Hemoglobin level, ferritin level, reticulocyte count